Fact Based List:
Top Ten U.S. Drugs (by sales) Losing Patent Exclusivity in 2021
Submitted by gmccalister on Tue, 05/25/2021 - 10:03
- Lucentis (Genentech/Roche) 2020 $1.6 Billion in sales
- Bystolic (AbbVie/Allergan) 2020 $600 Million in sales
- Vascepa (Amarin) 2020 $598 Million in sales
- Nothera (Lundbeck) 2020 $416 Million in sales
- Narcan (Emergent Biosolutions) 2020 $311 Million in sales
- Brovana (Sunovion) 2020 $275 Million in sales
- Sutent (Pfizer) 2020 $223 Million in sales
- Saphris (AbbVie/Allergan) 2020 $217 Million in sales
- Amitiza (Mallinckrodt) 2020 $180 Million in sales
- Feraheme (Amag Pharma) 2020 $150 Million in sales
Source: JDSupra, April 29, 2021
Source URL: https://www.jdsupra.com/legalnews/top-drugs-losing-patent-ex...
List Ratings: |
Lists You Might Also Be Interested In
Login or register to post comments